lmmuSAFE™ is a novel, lab-based biochip test for COVID-19 that enables highly quantitative determination of both the level and target location of SARS-CoV-2 antibodies in an individual. The tests answer 4 fundamental questions:
1. Confirming with high accuracy whether an individual has been infected with the virus that causes COVID-19.
2. Determine whether the level and target location of the antibodies in an individual are likely to offer protectivity.
3. Confirming that an individual has generated a sufficiently strong immune response to the vaccine to confer protection.
4. Retesting to confirm the status of ongoing protection and evaluating whether a booster vaccine is required.
lmmuSAFE™ utilises Sengenics’ patented KREX™ protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites. Multiple domains of SARS-CoV-2 Nucleocapsid and Spike proteins including both full-length and numerous truncated versions are used in the tests.
The biochip enables the determination of the target epitopes, titres and immunoglobulin class/sub-class (IgG, IgA, IgM; IgG1-4) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination. lmmuSAFE™ can also enable quantitative assessment of patient response in vaccination trials, including differentiation of whether observed antibody responses are due directly to the vaccine or to prior SARS-CoV-2 exposure.
ImmuSAFE™ can be utilised for vaccine clinical trials or sero-prevalence research studies.
The target epitope of antibodies produced following infection exhibit a significant level of diversity across a population. ImmuSAFE™ provides a more accurate determination of sero-prevalence by targeting multiple domains of SARS-CoV-2 proteins.
Some individuals produce antibodies that target locations which are neutralising (protective), whereas others produce non-neutralising antibodies. ImmuSAFE™ can be used to identify individuals who have high titres of potentially neutralising antibodies against SARS-CoV-2.
Investigate SARS-CoV-2 specific immunoreactivity in patients and healthy individuals for vaccine development, safety and efficacy determination in clinical trials.
As shown below, data from ImmuSAFE™ tests enable 3 major conclusions to be inferred:
Relative IgG titres in convalescent COVID-19 patient and healthy sera against different domains of SARS-CoV-2 nucleocapsid [For illustration purposes only].
The ImmuSAFE™ product range also includes other biochip-based tests that incorporate additional viral antigens. Content can be customised based on individualised requirements for vaccine clinical trials or sero-prevalence research studies.
High-throughput autoantibody screening protein array containing 1600+ autoantigens
Contains correctly folded antigens from SARS-CoV-2 and 25 other Corona and Influenza viruses
Obviates conventional blood draw and cold chain by only requiring dried blood spots on SEROMAX kit
© 2008 – 2020 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361
